EUVIMEDEUVIMED entdecken
Crossref

Accelerating IND ‐enabling toxicology studies using protein products from stable pools or pools of clones in Chinese hamster ovary cells

Yiwen Jiang, Lingxi Jiang, Zhongwei Yang, Xiaolin Liu, Yaoyao Wang, Man Ying, He Huang, Yiren Xu, Hang Zhou, Jincui Huang, Xuejun Gu, Weichang Zhou und 1 weitere

Biotechnology Progress · 2025

DOI: 10.1002/btpr.70040 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biotechnology Progress, 2025. Verfasst von Yiwen Jiang und 12 weiteren Autor:innen. Beteiligte Einrichtung: WuXi Biologics, Shanghai, China. Hauptthemen laut MEDLINE: Antibodies, Monoclonal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In recent years, accelerating Chemistry, Manufacturing, and Controls (CMC) workflows for clinical entry has become a critical focus in biologics development. Advances in the development of cell lines, cell culture processes, and analytical technologies have enabled the generation of more homogeneous stable pool populations with increased productivity. Leveraging the experience gained from the COVID‐19 product development, the strategic use of stable cell pools or a pool of clones for early‐stage non‐GMP material generation and process development has proven transformative in significantly reducing the CMC timeline to investigational new drug (IND). This study provides a comprehensive comparison of bioprocess performance and product quality attributes of materials produced from stable pools or a pool of clones (toxicology study materials) versus those from clonally derived cells (GMP clinical batches) across six First‐in‐Human (FIH) programs involving mAbs, bsAb, and Fc‐fusion proteins. The results demonstrate a strong alignment and the feasibility of using protein materials from stable pools or a pool of clones in toxicology studies. In conclusion, utilizing non‐clonal CHO cell‐derived material for preclinical studies offers a strategic approach that can be broadly applied to complex molecules across various disease areas, even under standard regulatory filings, accelerating the path to clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalCHO CellsCricetulusAnimalsHumansSARS-CoV-2COVID-19Cricetinae

Stichwörter der Autor:innen

CHO cell culturebiologics developmentclonecomparability studyfirst in human (FIH)investigational new drug (IND)stable pooltimeline acceleration

Substanzen

Antibodies, Monoclonal

Autor:innen und Institutionen

  • WuXi Biologics, Shanghai, China.
  • WuXi Biologics, Cranbury, New Jersey, USA.

ORCID-Profile: Ying Huang

Zitieren

APA

Jiang, Y., Jiang, L., Yang, Z., Liu, X., Wang, Y., Ying, M., Huang, H., Xu, Y., Zhou, H., Huang, J., Gu, X., Zhou, W., & Huang, Y. (2025). Accelerating IND ‐enabling toxicology studies using protein products from stable pools or pools of clones in Chinese hamster ovary cells. Biotechnology Progress. https://doi.org/10.1002/btpr.70040

Vancouver

Jiang Y, Jiang L, Yang Z, Liu X, Wang Y, Ying M, et al. Accelerating IND ‐enabling toxicology studies using protein products from stable pools or pools of clones in Chinese hamster ovary cells. Biotechnology Progress. 2025. doi:10.1002/btpr.70040

BibTeX
@article{Jiang2025,
  author = {Jiang, Yiwen and Jiang, Lingxi and Yang, Zhongwei and Liu, Xiaolin and Wang, Yaoyao and Ying, Man and Huang, He and Xu, Yiren and Zhou, Hang and Huang, Jincui and Gu, Xuejun and Zhou, Weichang and Huang, Ying},
  title = {Accelerating IND ‐enabling toxicology studies using protein products from stable pools or pools of clones in Chinese hamster ovary cells},
  journal = {Biotechnology Progress},
  year = {2025},
  doi = {10.1002/btpr.70040}
}
Kostenlos starten →